Cardiovascular Risk
63
12
14
34
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.6%
1 terminated out of 63 trials
97.1%
+10.6% vs benchmark
11%
7 trials in Phase 3/4
9%
3 of 34 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 34 completed trials
Clinical Trials (63)
Predication of Arterial Stiffness in Healthy Adults by Oral Health and Chewing Assessments
Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP)
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
Dose-Response to Resistance Exercise on Cardiovascular Health
Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study
Cardiovascular Risk in Patients With IBD
AI-THEROSCOPE: AI Detection of Subclinical Atherosclerosis From Retinal Images
Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors
Evaluation of Cardiovascular Risks Among the Participants of the ESC Congress 2025
Interdisciplinary Program to Improve Lifestyle in Chronic Pathology: Alt Pirineu Aran in Fit (APA-FIT)
Cf-PWV and TyG Index Study
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
Guideline Adherence in Dyslipidemia With Clinical Decision Support
Digital Prevention Program With Telephonic Coaching
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CVRISK-IT)
Canagliflozin and Myocardial Fibrosis